Peter Atadja

List of Publications by Year
in descending order

90 papers	10,616 citations	29994 54 h-index	45213 90 g-index
92 all docs	92 docs citations	92 times ranked	11147 citing authors

#	Article	IF	Citations
1	Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies. Journal of Medicinal Chemistry, 2022, 65, 5317-5333.	2.9	24
2	Discovery of Small-Molecule Antagonists of the H3K9me3 Binding to UHRF1 Tandem Tudor Domain. SLAS Discovery, 2018, 23, 930-940.	1.4	29
3	An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. Nature Chemical Biology, 2017, 13, 381-388.	3.9	259
4	Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy. Journal of Medicinal Chemistry, 2017, 60, 2215-2226.	2.9	86
5	Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells. Oncotarget, 2017, 8, 85085-85101.	0.8	32
6	Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED. PLoS ONE, 2017, 12, e0169855.	1.1	36
7	Histone Demethylase LSD1 Promotes Adipocyte Differentiation through Repressing Wnt Signaling. Cell Chemical Biology, 2016, 23, 1228-1240.	2.5	41
8	Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia. Clinical Epigenetics, 2015, 7, 2.	1.8	13
9	Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53. Nature Communications, 2015, 6, 8651.	5.8	134
10	Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood, 2014, 123, 1341-1352.	0.6	107
11	Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia. Molecular Cell, 2014, 53, 247-261.	4.5	252
12	Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6841-6846.	3.3	167
13	The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin. Clinical Cancer Research, 2012, 18, 2230-2239.	3.2	16
14	Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells. Molecular Cancer Therapeutics, 2012, 11, 973-983.	1.9	93
15	Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells. Clinical Cancer Research, 2012, 18, 6227-6238.	3.2	43
16	Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 21360-21365.	3.3	501
17	Biocatalytic Synthesis and Structure Elucidation of Cyclized Metabolites of the Deacetylase Inhibitor Panobinostat (LBH589). Drug Metabolism and Disposition, 2012, 40, 1041-1050.	1.7	12
18	ING1 and 5-Azacytidine Act Synergistically to Block Breast Cancer Cell Growth. PLoS ONE, 2012, 7, e43671.	1.1	30

#	Article	IF	Citations
19	Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. Oncotarget, 2012, 3, 1416-1427.	0.8	46
20	Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 2011, 54, 4752-4772.	2.9	54
21	Concurrent HDAC and mTORC1 Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated with Alterations in MicroRNA Expression. PLoS ONE, 2011, 6, e27178.	1.1	16
22	Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. Free Radical Biology and Medicine, 2011, 50, 313-322.	1.3	49
23	The design, synthesis and structureâ€“activity relationships of novel isoindoline-based histone deacetylase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4909-4912.	1.0	26
24	Antitumor activities and onâ€target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. International Journal of Cancer, 2011, 128, 2735-2747.	2.3	11
25	Structure of Human SMYD2 Protein Reveals the Basis of p53 Tumor Suppressor Methylation. Journal of Biological Chemistry, 2011, 286, 38725-38737.	1.6	55
26	In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica, 2010, 95, 794-803.	1.7	144
27	IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood, 2010, 115, 2430-2440.	0.6	88
28	Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. Blood, 2010, 116, 5306-5315.	0.6	46
29	Conformational Refinement of Hydroxamate-Based Histone Deacetylase Inhibitors and Exploration of 3-Piperidin-3-ylindole Analogues of Dacinostat (LAQ824). Journal of Medicinal Chemistry, 2010, 53, 2952-2963.	2.9	32
30	Synergistic action of the novel HSP90 inhibitor NVPâ€AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. European Journal of Haematology, 2010, 84, 337-344.	1.1	40
31	Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous Tâ€cell lymphoma models: Defining molecular mechanisms of resistance. International Journal of Cancer, 2010, 127, 2199-2208.	2.3	79
32	Polycomb Target Genes Are Silenced in Multiple Myeloma. PLoS ONE, 2010, 5, e11483.	1.1	81
33	Treatment with Panobinostat Induces Glucose-Regulated Protein 78 Acetylation and Endoplasmic Reticulum Stress in Breast Cancer Cells. Molecular Cancer Therapeutics, 2010, 9, 942-952.	1.9	76
34	Histone Deacetylase Inhibitors Activate NF-ÎºB in Human Leukemia Cells through an ATM/NEMO-related Pathway. Journal of Biological Chemistry, 2010, 285, 10064-10077.	1.6	57
35	Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-Mediated Potentiation of Bortezomib-Induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells. Clinical Cancer Research, 2010, 16, 4742-4754.	3.2	49
36	High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model. Clinical Cancer Research, 2009, 15, 4066-4076.	3.2	53

#	Article	IF	Citations
37	Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biology and Therapy, 2009, 8, 939-950.	1.5	84
38	The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. Journal of Pathology, 2009, 218, 467-477.	2.1	46
39	Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges. Cancer Letters, 2009, 280, 233-241.	3.2	358
40	Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: Potential role of histone deacetylase 6. Radiotherapy and Oncology, 2009, 92, 125-132.	0.3	40
41	Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77â€“based mechanism. Blood, 2009, 113, 4038-4048.	0.6	50
42	The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood, 2009, 114, 380-393.	0.6	108
43	Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood, 2009, 114, 2733-2743.	0.6	336
44	Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood, 2009, 114, 5024-5033.	0.6	165
45	A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL. Journal of Thoracic Oncology, 2009, 4, 149-160.	0.5	32
46	Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of a Novel Histone Deacetylase Inhibitor, LAQ824, in Human Colon Carcinoma Cells and Xenografts. Neoplasia, 2008, 10, 303-313.	2.3	41
47	Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma. Clinical Cancer Research, 2008, 14, 4500-4510.	3.2	286
48	Combination Strategy Targeting the Hypoxia Inducible Factor-1Î± with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors. Clinical Cancer Research, 2008, 14, 3589-3597.	3.2	105
49	Epigenetic Silencing of the Tetraspanin CD9 during Disease Progression in Multiple Myeloma Cells and Correlation with Survival. Clinical Cancer Research, 2008, 14, 2918-2926.	3.2	46
50	Inhibition of Histone Deacetylases Promotes Ubiquitin-Dependent Proteasomal Degradation of DNA Methyltransferase 1 in Human Breast Cancer Cells. Molecular Cancer Research, 2008, 6, 873-883.	1.5	143
51	Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2008, 14, 6663-6673.	3.2	115
52	Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Molecular Cancer Therapeutics, 2008, 7, 3285-3297.	1.9	104
53	Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. Neuro-Oncology, 2008, 10, 309-319.	0.6	38
54	Role of Acetylation and Extracellular Location of Heat Shock Protein 90Î± in Tumor Cell Invasion. Cancer Research, 2008, 68, 4833-4842.	0.4	213

#	Article	IF	Citations
55	Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitorâ€“resistant acute myeloid leukemia cells. Blood, 2008, 112, 2896-2905.	0.6	80
56	The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Phâ^' acute lymphoblastic leukemia cells. Blood, 2008, 111, 5093-5100.	0.6	134
57	HDAC6 inhibition enhances 17-AAGâ€“mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood, 2008, 112, 1886-1893.	0.6	176
58	Molecular and Cellular Basis for the Anti-Proliferative Effects of the HDAC Inhibitor LAQ824. Novartis Foundation Symposium, 2008, , 249-268.	1.2	23
59	Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-Î± Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90. Clinical Cancer Research, 2007, 13, 4882-4890.	3.2	138
60	Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biology and Therapy, 2007, 6, 64-69.	1.5	143
61	Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Molecular Cancer Therapeutics, 2007, 6, 70-81.	1.9	74
62	Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptorâ€“dependent human lung cancer cells. Molecular Cancer Therapeutics, 2007, 6, 2515-2524.	1.9	117
63	Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation. Clinical Cancer Research, 2007, 13, 1140-1148.	3.2	75
64	Efficacy of Panobinostat (LBH589) in CTCL Cell Lines and a Murine Xenograft Model: Defining Molecular Pathways of Panobinostat Activity in CTCL.. Blood, 2007, 110, 1375-1375.	0.6	3
65	Efficacy of Panobinostat (LBH589) in Multiple Myeloma Cell Lines and In Vivo Mouse Model: Tumor-Specific Cytotoxicity and Protection of Bone Integrity in Multiple Myeloma.. Blood, 2007, 110, 1510-1510.	0.6	3
66	Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1Î±. Cancer Research, 2006, 66, 8814-8821.	0.4	292
67	Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Ablâ€“expressing human leukemia cells. Blood, 2006, 108, 645-652.	0.6	142
68	Aggresome induction by proteasome inhibitor bortezomib and Î±-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood, 2006, 108, 3441-3449.	0.6	328
69	HDAC Inhibitors. , 2006, , 315-332.		4
70	In vivo Biological Activity of the Histone Deacetylase Inhibitor LAQ824 Is detectable with 3â€²-Deoxy-3â€²-[18F]Fluorothymidine Positron Emission Tomography. Cancer Research, 2006, 66, 7621-7629.	0.4	68
71	The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug Resistance. Cancer Research, 2006, 66, 5781-5789.	0.4	233
72	Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589. Clinical Cancer Research, 2006, 12, 634-642.	3.2	264

#	Article	IF	Citations
73	Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Molecular Cancer Therapeutics, 2006, 5, 3096-3104.	1.9	115
74	Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells. Molecular Cancer Therapeutics, 2005, 4, 1772-1785.	1.9	28
75	Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood, 2005, 105, 1768-1776.	0.6	332
76	Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Molecular Cancer Therapeutics, 2005, 4, 1311-1319.	1.9	94
77	Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90. Journal of Biological Chemistry, 2005, 280, 26729-26734.	1.6	694
78	Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824. Cancer Research, 2004, 64, 689-695.	0.4	141
79	Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells. Cancer Research, 2004, 64, 2580-2589.	0.4	215
80	Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3. Clinical Cancer Research, 2004, 10, 4991-4997.	3.2	128
81	The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584. Cancer Research, 2004, 64, 6626-6634.	0.4	229
82	Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica, 2004, 89, 419-26.	1.7	47
83	Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Foundation Symposium, 2004, 259, 249-66; discussion 266-8, 285-8.	1.2	16
84	N-Hydroxy-3-phenyl-2-propenamides as Novel Inhibitors of Human Histone Deacetylase with in Vivo Antitumor Activity:â€‰ Discovery of (2E)-N-Hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). Journal of Medicinal Chemistry, 2003, 46, 4609-4624.	2.9	129
85	NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood, 2003, 102, 2615-2622.	0.6	220
86	Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Research, 2003, 63, 5126-35.	0.4	218
87	Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Molecular Cancer Therapeutics, 2003, 2, 971-84.	1.9	191
88	Inhibitors of Human Histone Deacetylase:â€‰ Synthesis and Enzyme and Cellular Activity of Straight Chain Hydroxamates. Journal of Medicinal Chemistry, 2002, 45, 753-757.	2.9	112
89	Regulation of transcription factor activity during cellular aging. Biochemistry and Cell Biology, 1996, 74, 523-534.	0.9	33
90	Overexpression of Cyclin D1 Blocks Proliferation of Normal Diploid Fibroblasts. Experimental Cell Research, 1995, 217, 205-216.	1.2	84